Document Type	|	Form
Index Number	|	Registry 109
Version Number	|	1.0
Title	|	Disease status HCT CT IST Day 0
Author	|	Annelot van Amerongen
Authorised By	|	Annelot van Amerongen
Authorised On	|	22-Aug-2023
Release Date:		22-Aug-2023

EBMT Centre Identification Code (CIC): _ _ _ _
Hospital Unique Patient Number (UPN): _ _ _ _ _ _ _ _ _ _ _ _
Patient Number in EBMT database: _ _ _ _ _ _ _ _

Treatment Type ☐ HCT ☐ CT ☐ IST ☐ Other

Treatment Date _ _ _ _/ _ _/ _ _ *(YYYY/MM/DD)*

DISEASE STATUS AT HCT/CT/IST
Day 0

PATIENT STATUS
(All Diagnoses)

Date of HCT/CT/IST: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*
(or planned date of HCT/CT/IST if patient died before)

Survival status at HCT/CT/IST:

☐ Alive
☐ Died after conditioning but before HCT/CT/IST
☐ Died after apheresis but before cell infusion

Date of death: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*

Main cause of death:
(check only one main cause)

☐ Relapse or progression/persistent disease	
☐ Secondary malignancy	
☐ Cellular therapy-related	**Select treatment related cause:** ☐ Graft versus host disease ☐ Non-infectious complication ☐ Infectious complication: *(select all that apply)* ☐ Bacterial infection ☐ Viral infection ☐ Fungal infection ☐ Parasitic infection ☐ Infection with unknown pathogen
☐ HCT-related	
☐ Unknown	
☐ Other; specify: _____	

Performance status at initiation of HCT/CT/IST *(choose only one)*:

Type of scale used:	Score:
☐ Karnofsky ☐ Lansky	☐ 10 ☐ 20 ☐ 30 ☐ 40 ☐ 50 ☐ 60 ☐ 70 ☐ 80 ☐ 90 ☐ 100
☐ ECOG	☐ 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4

Patient weight at initiation of HCT/CT/IST: _____ kg

Patient height at initiation of HCT/CT/IST: _____ cm

COMORBIDITY INDEX

Sorror et al., Blood, 2005 Oct 15; 106(8): 2912-2919: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895304

Was there any clinically significant co-existing disease or organ impairment as listed below at time of patient assessment prior to the preparative regimen?

☐ No

☐ Yes *(indicate each comorbidity below)*

☐ Unknown

COMORBIDITY:	Definition:	
Solid tumour, previously present	Treated at any time point in the patient's past history, excluding non-melanoma skin cancer. Indicate type: _____	☐ No ☐ Yes ☐ Not evaluated
Inflammatory bowel disease	Crohn's disease or ulcerative colitis	☐ No ☐ Yes ☐ Not evaluated
Rheumatologic	SLE, RA, polymyositis, mixed CTD or polymyalgia rheumatica	☐ No ☐ Yes ☐ Not evaluated
Infection	Requiring continuation of antimicrobial treatment after day 0	☐ No ☐ Yes ☐ Not evaluated
Diabetes	Requiring treatment with insulin or oral hypoglycaemics but not diet alone	☐ No ☐ Yes ☐ Not evaluated
Renal: moderate/severe	Serum creatinine > 2 mg/dL or >177 µmol/L, on dialysis, or prior renal transplantation	☐ No ☐ Yes ☐ Not evaluated
Hepatic: mild	Chronic hepatitis, bilirubin between Upper Limit Normal (ULN) and 1.5 x ULN, or AST/ALT between ULN and 2.5 × ULN	☐ No ☐ Yes ☐ Not evaluated
Hepatic: moderate/severe	Liver cirrhosis, bilirubin greater than 1.5 × ULN, or AST/ALT greater than 2.5 × ULN	☐ No ☐ Yes ☐ Not evaluated
Arrhythmia	Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias	☐ No ☐ Yes ☐ Not evaluated
Cardiac	Coronary artery disease, congestive heart failure, myocardial infarction, EF ≤ 50%, or shortening fraction in children (<28%)	☐ No ☐ Yes ☐ Not evaluated
Cerebrovascular disease	Transient ischaemic attack or cerebrovascular accident	☐ No ☐ Yes ☐ Not evaluated
Heart valve disease	Except mitral valve prolapse	☐ No ☐ Yes ☐ Not evaluated
Pulmonary: moderate	DLco and/or FEV1 66-80%, or dyspnoea on slight activity	☐ No ☐ Yes ☐ Not evaluated
Pulmonary: severe	DLco and/or FEV1 ≤ 65%, or dyspnoea at rest or requiring oxygen	☐ No ☐ Yes ☐ Not evaluated
Obesity	Patients with body mass index > 35 kg/m^2	☐ No ☐ Yes ☐ Not evaluated
Peptic ulcer	Requiring treatment	☐ No ☐ Yes ☐ Not evaluated
Psychiatric disturbance	Depression or anxiety requiring psychiatric consultation or treatment	☐ No ☐ Yes ☐ Not evaluated

COMORBIDITY INDEX continued

Sorror et al., Blood, 2005 Oct 15; 106(8): 2912-2919: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895304

Was there any additional major clinical abnormality not listed above and present prior to the preparative regimen?

☐ No
☐ Yes; specify: _____

Were there any autoimmune diseases? ☐ No
☐ Yes; specify: _____
Date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*

COMORBIDITY INDEX

Inborn Errors of Immunity only

COMORBIDITY:	Definition:	
Chronic lung disease	Bronchiectasis, interstitial pneumonitis, GLILD, oxygen dependency, structural lung disease (e.g. pneumatoceles)	☐ No ☐ Yes ☐ Not evaluated
Previous haematological malignancy	Leukaemia, lymphoma, myelodysplastic syndrome (MDS)	☐ No ☐ Yes ☐ Not evaluated
Failure to thrive	Weight <3rd percentile or requirement for (par)enteral feeding	☐ No ☐ Yes ☐ Not evaluated
Active infection at HCT	Any infection requiring therapy in the immediate pre HCT period	☐ No ☐ Yes ☐ Not evaluated
Lymphoproliferation	I.e. splenomegaly, organ specific lymphoproliferation	☐ No ☐ Yes ☐ Not evaluated
Pre-HCT organ impairment	Infectious or non-infectious (including neurologic)	☐ No ☐ Yes ☐ Not evaluated
Autoimmunity/autoinflammation	Active at HCT (includes patients in remission but on immunomodulatory treatment within 3 months before HCT)	☐ No ☐ Yes ☐ Not evaluated

SARS-CoV-2 RELATED QUESTIONS

Did the patient have a <u>symptomatic</u> SARS-CoV-2 infection *(positive PCR or antigen test)* **in the 3 months prior to the day of treatment?** *Note: do not report here if the infection was asymptomatic.*

☐ No

☐ Yes; Date: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*

Did the patient have an ongoing SARS-CoV-2 infection *(positive PCR or antigen test)* **at the moment of the start of the conditioning regimen?**

☐ No

☐ Yes

END OF GENERAL SECTION

TO COMPLETE DISEASE STATUS AT HCT/CT/IST REPORT, PLEASE FILL IN THE APPLICABLE DIAGNOSE-SPECIFIC QUESTIONS ATTACHED

Status at treatment

Complete only for one main indication diagnosis for which this HCT/CT/IST is given.

ACUTE LEUKAEMIAS
Status at treatment

Status:

☐ Primary induction failure
☐ 1st complete haematological remission (CR)
☐ 1st relapse
☐ 2nd complete haematological remission (CR)
☐ 2nd relapse
☐ 3rd or higher complete haematological remission (CR)
☐ 3rd or higher relapse
☐ Unknown

Number of induction courses: ____ ☐ Unknown

Date of the last relapse before this treatment: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)* ☐ Not applicable
(if applicable)

CD19 expression at the last relapse: ☐ Positive ☐ Negative ☐ Not evaluated

Bone marrow burden (% blasts): _____ % ☐ Not evaluated ☐ Unknown

Involvement at time of treatment:

☐ Medullary only
☐ Extra-medullary only
☐ Both, medullary and extra-medullary
☐ Unknown

Organs involved at time of treatment:

Skin:	☐ No	☐ Yes	☐ Not evaluated
CNS:	☐ No	☐ Yes	☐ Not evaluated
Testes/Ovary:	☐ No	☐ Yes	☐ Not evaluated
Other; specify: _____	☐ No	☐ Yes	

Complete this section only if the disease status is CR

Minimal residual disease (MRD) at initiation of treatment:

☐ Positive
☐ Negative
☐ Not evaluated

Date MRD status evaluated: _ _ _ _ / _ _ / _ _ *(YYYY/MM/DD)*

Sensitivity of MRD assay:

☐ $<10^{-5}$
☐ $<10^{-4}$
☐ $<10^{-3}$
☐ Other; specify: _____

Method used:

☐ PCR
☐ Flow cytometry
☐ Other; specify: _____

CHRONIC LEUKAEMIAS
Chronic Myelogenous Leukaemias (CML) - Status at treatment

Status:

☐ Chronic phase (CP)

Number:	Haematological remission:	Cytogenetic remission:	Molecular remission:
☐ 1st	☐ No	☐ No	☐ No
☐ 2nd	☐ Yes	☐ Yes	☐ Yes
☐ 3rd or higher	☐ Not evaluated	☐ Not evaluated	☐ Not evaluated
☐ Unknown	☐ Unknown	☐ Unknown	☐ Unknown

☐ Accelerated phase

Number:
- ☐ 1st
- ☐ 2nd
- ☐ 3rd or higher
- ☐ Unknown

☐ Blast crisis

Number:
- ☐ 1st
- ☐ 2nd
- ☐ 3rd or higher
- ☐ Unknown

CHRONIC LEUKAEMIAS
Chronic Lymphocytic Leukaemias (CLL) - Status at treatment

Status:

- ☐ Complete remission (CR)
- ☐ Partial remission (PR)
- ☐ Stable disease (SD)
- ☐ Relapse (untreated)
- ☐ Progressive disease (PD)
- ☐ Never treated
- ☐ Unknown

Complete this section only if the disease status is CR

Minimal residual disease (MRD) at initiation of treatment:
(by FACS or PCR)

- ☐ Negative
- ☐ Positive
- ☐ Not evaluated

CHRONIC LEUKAEMIAS
Prolymphocytic (PLL) and Other Chronic Leukaemias
Status at treatment

Status:

- ☐ Complete remission (CR)
- ☐ Partial remission (PR)
- ☐ Stable disease (SD)
- ☐ Relapse (untreated)
- ☐ Progressive disease (PD)
- ☐ Never treated
- ☐ Unknown

LYMPHOMAS
Status at treatment

Status:

☐ Complete remission (CR)
- ☐ Unconfirmed (CRU*) ☐ Confirmed
- ** CRU: Complete response with persistent scan abnormalities of unknown significance*

☐ Partial response (PR) with or without prior CR

☐ Stable disease

☐ Untreated relapse from previous CR / untreated progression from previous PR
- Histopathological verification of relapse: ☐ No ☐ Yes

☐ Chemorefractory relapse or progression, including primary refractory disease
- Histopathological verification of relapse: ☐ No ☐ Yes

☐ Disease status unknown

Technique used for disease assessment:

☐ CT scan
☐ PET
☐ MRI

Parameters for international prognostic indices:

Age at diagnosis: _____ years (*this is automatically calculated in the database*)						
LDH levels elevated:	☐ No	☐ Yes	☐ Not evaluated			
Ann Arbor staging:	☐ I	☐ II	☐ III	☐ IV	☐ Not evaluated	
ECOG performance status:	☐ 0	☐ 1	☐ 2	☐ 3	☐ 4	☐ Not evaluated
> 1 extranodal site involved:	☐ No	☐ Yes	☐ Not evaluated			
> 4 nodal sites involved:	☐ No	☐ Yes	☐ Not evaluated			
Hemoglobin < 120g/L:	☐ No	☐ Yes	☐ Not evaluated			
White Blood Cell count:	_____ x 10^9 cells/L				☐ Not evaluated	

MYELODYSPLASTIC SYNDROMES (MDS)
Status at treatment

Classification at treatment (WHO 2016):

☐ MDS with single lineage dysplasia (MDS-SLD)
☐ MDS with ring sideroblasts (MDS-RS)
☐ Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
☐ MDS with multilineage dysplasia (MDS-MLD)
☐ MDS-RS with single lineage dysplasia (MDS-RS-SLD)
☐ MDS-RS with multilineage dysplasia (MDS-RS-MLD)
☐ MDS with excess blasts (EB)-1
☐ MDS with excess blasts (EB)-2
☐ Refractory cytopenia of childhood
☐ MDS unclassifiable (MDS-U)

Status:

☐ Complete remission (CR)	Number: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Improvement but no CR	
☐ Primary refractory phase (no change)	
☐ Relapse	Number: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Progression/Worsening	
☐ Never treated (supportive care or treatment without chemotherapy)	
☐ Unknown	

COMBINED MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS (MDS/MPN) - Status at treatment

Classification:

☐ Chronic myelomonocytic leukaemia (CMMoL, CMML):	**CMML type:**	☐ Myelodysplastic ☐ Myeloproliferative
	WHO subclassification (2016):	☐ CMML-0 ☐ CMML-1 ☐ CMML-2 ☐ Unknown
☐ Juvenile myelomonocytic leukaemia (JCMMoL, JMML, JCML, JCMML)		
☐ Atypical CML (t(9;22) negative and BCR-ABL1 negative)		
☐ MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)		
☐ MDS/MPN unclassifiable		

Status:

☐ Complete remission (CR)	Number: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Improvement but no CR	
☐ Primary refractory phase (no change)	
☐ Relapse	Number: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Progression/Worsening	
☐ Never treated (supportive care or treatment without chemotherapy)	
☐ Unknown	

MYELOPROLIFERATIVE NEOPLASMS (MPN)
Status at treatment

Classification at treatment (WHO 2016):

☐ Primary myelofibrosis (Chronic idiopathic myelofibrosis; fibrosis with myeloid metaplasia)
☐ Secondary myelofibrosis (Transformed to myelofibrosis from PV/ET)
☐ Polycythaemia vera (PV)
☐ Essential or primary thrombocythaemia (ET)
☐ Hyper eosinophilic syndrome (HES)
☐ Chronic eosinophilic leukaemia (CEL)
☐ Chronic neutrophilic leukaemia
☐ Systemic mastocytosis
☐ Mast cell leukaemia
☐ Mast cell sarcoma
☐ MPN not otherwise specified
☐ Myeloid and lymphoid neoplasms with FGFR1 abnormalities (Stem cell leukaemia-lymphoma syndrome, 8p11 syndrome)
☐ Myeloid and lymphoid neoplasms with PDGFRA rearrangement
☐ Myeloid and lymphoid neoplasms with PDGFRB rearrangement
☐ Myeloid and lymphoid neoplasms with PCM1-JAK2 rearrangement
☐ Transformed to AML
☐ Other; specify: _____

Status:

☐ Complete remission (CR)	Number: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Improvement but no CR	
☐ Primary refractory phase (no change)	
☐ Relapse	Number: ☐ 1st ☐ 2nd ☐ 3rd or higher ☐ Unknown
☐ Progression/Worsening	
☐ Never treated (supportive care or treatment without chemotherapy)	
☐ Unknown	

MYELOPROLIFERATIVE NEOPLASMS (MPN)
Status at treatment

Blast count *(peripheral blood)*: _____ **%** ☐ Not evaluated ☐ Unknown

Spleen size: _____ cm (*below costal margin)* ☐ Not evaluated ☐ Unknown

Spleen span in ultrasound or CT scan: _____ cm (maximum diameter) ☐ Not evaluated ☐ Unknown

JAK inhibitor exposure between diagnosis and treatment:

☐ No
☐ Yes
☐ Unknown

Was a JAK inhibitor continued during conditioning?

☐ No
☐ Yes: Dose: _____ mg/day

Start date: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD)

End date: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Response status:

☐ Spleen response
☐ No response/loss of response
☐ Primary resistance
☐ Unknown

Myelofibrosis only:

DIPSS Risk score at treatment:

☐ Low risk
☐ Intermediate - 1
☐ Intermediate - 2
☐ High risk
☐ Not evaluated
☐ Unknown

MIPSS70 score at treatment:

☐ Low risk
☐ Intermediate
☐ High risk
☐ Not evaluated
☐ Unknown

Secondary myelofibrosis only (post-ET MF, post-PV MF):

MYSEC-PM score at time of secondary MF diagnosis:

☐ Low risk
☐ Intermediate - 1
☐ Intermediate - 2
☐ High risk
☐ Not evaluated
☐ Unknown

PLASMA CELL DISORDERS (PCD) incl. MULTIPLE MYELOMA (MM)

Status at treatment

Status:

☐ MRD negative CR	
☐ Stringent complete remission (sCR)	Number:
☐ Complete remission (CR)	☐ 1st
☐ Very good partial remission (VGPR)	☐ 2nd
☐ Partial remission (PR)	☐ 3rd or higher
☐ Stable disease / No change	☐ Unknown
☐ Progression	
☐ Never treated	
☐ Unknown	

SOLID TUMOURS
Status at treatment

Status:

☐ Adjuvant

☐ Never treated *(upfront)*

☐ Stable disease/no response

☐ Complete remission (CR)

- ☐ Unconfirmed (UCR*)
- ☐ Confirmed

** UCR: complete response with persistent scan abnormalities of unknown significance*

Number:

- ☐ 1st
- ☐ 2nd
- ☐ 3rd or higher
- ☐ Unknown

☐ 1st partial response (PR1)

☐ Relapse

Number:

- ☐ 1st
- ☐ 2nd
- ☐ 3rd or higher
- ☐ Unknown

Sensitivity to chemotherapy:

- ☐ Sensitive
- ☐ Resistant
- ☐ Untreated

☐ Progressive disease (PD)

☐ Unknown

Complete this section only if the disease status is not CR

Organ involvement at time of this treatment:

- ☐ Nodes below diaphragm
- ☐ Nodes above diaphragm
- ☐ CNS
- ☐ Liver
- ☐ Bone
- ☐ Lung
- ☐ Soft tissue
- ☐ Other; specify: _____

Germ cell tumours only:

Risk category at disease recurrence (or platinum refractoriness) following first line chemotherapy:
Note: according to International Prognostic Factors Study Group classification published in 2010.

- ☐ Very low
- ☐ Low
- ☐ Intermediate
- ☐ High
- ☐ Very high
- ☐ Not evaluated

AUTOIMMUNE DISEASES
Status at Mobilisation

Status:

Systemic sclerosis only:

SSc subset:

☐ Diffuse cutaneous
☐ Limited cutaneous
☐ Sine scleroderma
☐ Other; specify: _____

Assessments at time of mobilisation *(within 3 months before mobilisation)*:

Creatinine Clearance (Cockroft formula): _____ ml/min ☐ Unknown

Proteinuria: _____ g/24hrs ☐ Unknown

Modified Rodnan Skin Score (0-51): _____ ☐ Unknown

DLCO (corrected for Hb): _____ % ☐ Unknown

Mean Pulmonary Arterial Systolic Pressure [PASP] *(from right heart catheterisation)*: _____ mm Hg

GI Involvement: ☐ No ☐ Yes ☐ Not evaluated ☐ Unknown

Systemic lupus erythematosus only:

Assessments at time of mobilisation *(within 3 months before mobilisation)*:

SLEDAI-2K Score: _____ ☐ Not evaluated ☐ Unknown

Multiple sclerosis only:

Status at time of mobilisation *(within 3 months before mobilisation)*:

☐ Primary progressive
☐ Secondary progressive
☐ Relapsing/remitting
☐ Other; specify: _____

Assessments at time of mobilisation *(within 3 months before mobilisation)*:

EDSS (1-10): _____ ☐ Not evaluated

Number of gadolinium enhancing lesions present on MRI brain scan: _____ ☐ Unknown

Crohn's disease only:

Assessments at time of mobilisation *(within 3 months before mobilisation)*:

CDAI (0-700): _____ ☐ Not evaluated ☐ Unknown

Serum albumin: _____ g/L ☐ Unknown

HAEMOGLOBINOPATHIES
Status at treatment

Ferritin level : _____ **ng/mL** ☐ Not evaluated ☐ Unknown

Number of red blood cell transfusions:
- ☐ <20 units
- ☐ 20 to 50 units
- ☐ >50 units
- ☐ None
- ☐ Unknown

Liver iron concentration: _____ mg/g dry weight

Pre-existing liver disease?

☐ No

☐ Yes: **Hepatitis:**
- ☐ Absent
- ☐ Chronic persistent hepatitis
- ☐ Chronic active hepatitis

Liver biopsy performed? ☐ No

☐ Yes: **Liver fibrosis (Ishak staging):**
- ☐ F0 (no fibrosis)
- ☐ F1 (partial fibrosis)
- ☐ F2 (general fibrosis)
- ☐ F3 (partial bridging in fibrosis)
- ☐ F4 (general bridging in fibrosis)
- ☐ F5 (near cirrhosis)
- ☐ F6 (cirrhosis)

Pre-existing cardiac disease?

☐ No

☐ Yes: **Cardiac echography ejection fraction:** ☐ No ☐ Yes

Cardiovascular magnetic resonance (CMR) T2: _____ mg/g dry weight

Sickle cell disease only

Chronic transfusion program:
- ☐ No
- ☐ Yes

HAEMOGLOBINOPATHIES
Status at treatment

Pre-treatment complications (Sickle cell disease only):

(check all that apply)

☐ **Cerebrovascular disease**

Abnormal Doppler	☐ No	☐ Yes	☐ Not evaluated
Stroke	☐ No	☐ Yes	☐ Not evaluated
Haemorrhage	☐ No	☐ Yes	☐ Not evaluated
Arteriopathy	☐ No	☐ Yes	☐ Not evaluated
Moyamoya disease	☐ No	☐ Yes	☐ Not evaluated
Silent infarcts	☐ No	☐ Yes	☐ Not evaluated

☐ **Renal involvement**

Microalbumin level _____ mg/g ☐ Not evaluated

Glomerular filtration rate _____ mL/min/1.73m^2 ☐ Not evaluated

Avascular necrosis ☐ No ☐ Yes ☐ Not evaluated

Hyperhaemolysis or autoimmune haemolytic anaemia:
☐ No
☐ Yes: ☐ Hyperhaemolysis ☐ Autoimmune haemolytic anaemia
☐ Not evaluated

☐ **Other SCD related complications**

Acute chest syndrome	☐ No	☐ Yes	☐ Not evaluated
Vaso-occlusive crisis	☐ No	☐ Yes	☐ Not evaluated
Priapism	☐ No	☐ Yes	☐ Not evaluated
Pulmonary artery pressure	☐ No	☐ Yes	☐ Not evaluated
Chronic lung disease	☐ No	☐ Yes	☐ Not evaluated

Endocrinopathies pre-existing to HCT (Thalassemia only):

Hypothyroidism	☐ No	☐ Yes	☐ Not evaluated
Hypoparathyroidism	☐ No	☐ Yes	☐ Not evaluated
Diabetes mellitus	☐ No	☐ Yes	☐ Not evaluated
Osteoporosis	☐ No	☐ Yes	☐ Not evaluated
Gonadal dysfunction	☐ No	☐ Yes	☐ Not evaluated
Growth impairment	☐ No	☐ Yes	☐ Not evaluated